Publikationen, an denen er mitarbeitet Rubén Pío Osés (4)

2022

  1. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Drugsniper, a tool to exploit loss-of-function screens, identifies CREBBP as a predictive biomarker of VOLASERTIB in small cell lung carcinoma (SCLC)

    Cancers, Vol. 12, Núm. 7, pp. 1-18

2013

  1. Multiscale in situ analysis of the role of dyskerin in lung cancer cells

    Integrative Biology (United Kingdom), Vol. 5, Núm. 2, pp. 402-413